Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
about
Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemiaNew Developments in Chronic Myeloid Leukemia: Implications for TherapyKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceRole of solute carriers in response to anticancer drugsOne more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a "hypoxic" environment.Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft ModelsCancer stem cells in basic science and in translational oncology: can we translate into clinical application?Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiationDrug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanismsAbcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitroSensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib eraAHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cellsTumour heterogeneity and cancer cell plasticityA novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy.AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia.Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells.Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinibBCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cellsWT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase.Bcl2 is not required for the development and maintenance of leukemia stem cells in mice.Chronic myeloid leukemia: mechanisms of blastic transformationIsolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.Rank-rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures.Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapiesThe elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylateWnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.Targeted inhibition of kinases in cancer therapyImproved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.E- and p-selectins are essential for repopulation of chronic myelogenous and chronic eosinophilic leukemias in a scid mouse xenograft modelThe challenge of exploiting ABCG2 in the clinic.IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients.Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.
P2860
Q21245701-2B3C0F47-20DE-47CD-AFD6-E3F6F07C8E27Q26745669-DB779D3F-3097-4C12-AD69-5D2E0AF0DD69Q26849792-9EF7B8A1-562F-4C2A-A00E-EFDC7A858591Q26865927-0711DA1D-CDA0-45D3-980F-326200D1F4E3Q27027625-5FC2FC9A-0BFF-4839-BC08-C795C2724447Q27692583-8F3F3B03-79DD-4157-A8EE-290583A08B13Q28076328-8B245720-0376-4920-AF56-9FC771A9F5CEQ28081844-FEB2996F-6707-4B1B-B3B1-AB1DB05E5356Q28397002-9908B6B7-9707-439B-953B-F95EA2B53840Q28477091-25A42066-93A8-4E53-BE21-B49DC88A66CCQ28477903-388FAB49-68E3-4C69-AE62-638287328675Q28486093-3373D3FA-B6B3-405E-A529-D2C3FC98792DQ28586026-734ED55C-0340-4DF8-A72A-2ED60210C601Q29617990-70AA7152-A328-460A-8033-5D9F0189B67FQ30008755-EF72A005-47D1-4EF4-A31A-497E1CDCDB1DQ30010179-CD793369-F42C-46DE-94F2-3EFF98061415Q30588887-0EB85F85-BEDE-42AC-8A75-FD158973FEF5Q33561227-068EC91E-6637-4798-AEC0-C8E901BE1AC2Q33620053-954C678A-00CA-4803-8004-47436749FBD7Q33707394-46A93494-2567-4946-915C-94539A74CE9CQ33806036-19C5CA79-B1A5-42A4-866F-BBF2EEBF0BD2Q33814519-F6B6C4AD-0F01-45B8-A122-13DC3640D894Q33947776-9C4C5979-F9C0-4F77-86E8-DACF3A511395Q33968037-293D8509-06D3-48CE-B8DB-92282FD47A40Q34136730-D07A1D70-DF79-4A97-B7B9-7276438839F0Q34146410-C7732819-A0E5-4F6B-B43C-B7F13D1D2009Q34158454-D7319030-9FA6-4323-967B-00EDCFF2326FQ34167708-BCCDFADE-3972-4B05-A61A-7C1E5A41AF53Q34170309-441941A7-D824-439D-A412-A4ABCB232A91Q34183433-E013C235-1ACA-4BE6-8496-CA0B33AE93EBQ34184723-2A9CD845-C7C3-4AD2-8028-85D4D138C520Q34348134-7CBEB2C2-2DF7-4F3E-B35E-47D9076C77F7Q34683348-1E761D3D-DCDA-4760-96CC-08B169083DF2Q34792248-2930FFE0-B570-4014-A1D6-D14EB35F3C3AQ34871636-69936D12-3EE3-4EBF-85A3-CC8F446A4581Q34906157-CBC98B9D-1571-4F98-84D0-FB6055853DC6Q34968909-2398DD5B-6B08-4CDF-888D-BA68BB27FD4CQ35016953-0BA7BFE1-0C3E-4692-BCE3-801AB2D7DFFDQ35459525-1232332D-0030-4815-8F3C-9244A57188AFQ35640320-AAEAE8E0-1944-49D9-A50D-B142B27B0B46
P2860
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Chronic myeloid leukemia stem ...... to BCR-ABL targeted therapies.
@en
type
label
Chronic myeloid leukemia stem ...... to BCR-ABL targeted therapies.
@en
prefLabel
Chronic myeloid leukemia stem ...... to BCR-ABL targeted therapies.
@en
P2093
P356
P1433
P1476
Chronic myeloid leukemia stem ...... to BCR-ABL targeted therapies.
@en
P2093
Gasparetto M
P2888
P304
P356
10.1038/SJ.LEU.2404609
P577
2007-03-01T00:00:00Z
P5875
P6179
1038469614